UroGen Q2 FY26 net loss narrows to $14.4 million; revenue rises to $72.5 million

Reuters2026/08/05 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

UroGen posted Q2 2026 revenue of $72.5 million, up from $24.2 million a year earlier; net loss narrowed to $14.4 million.
ZUSDURI revenue climbed 73% quarter-over-quarter to $50.4 million; operating income was $111,000.
SG&A expenses rose to $48.4 million, reflecting ZUSDURI commercial activities; R&D expenses eased to $17.3 million.
Cash, cash equivalents and marketable securities totaled $108 million; full-year operating expense guidance increased to $260 million-$270 million.
Management cited a new U.S. patent allowance expected to protect ZUSDURI and UGN-103 into July 2044; UGN-103 remains on track for an NDA in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050800PRIMZONEFULLFEED9803967) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

UroGen Q2 FY26 net loss narrows to $14.4 million; revenue rises to $72.5 million

You may also like

Crypto prices